Which of the stakeholders who will be affected by the legislation in the situation below:
Biotech medicines---proteins made by modifying the DNA of bacteria, yeast or mammal cells and infused into sick patients---are the fastest-growing category of health spending. Sales reached $40 billion in 2006, when reports indicated there were more than 400 biotech products being synthesized to treat cancer, AIDS, diabetes, Alzheimer's, and a hundred other diseases. The manufacture of biotechs is more complex and costly than conventional medicine, and the cost to patients can run as high as $25,000-50,000 a year. Some members of Congress have introduced legislation that would give consumers access to lower-cost copies; one would authorize the FDA to approve safe, lower-cost versions of biotechnology drugs without the full range of tests normally required for new products.
The stakeholders who will be affected by the legislation in this situation will be the patients and the manufacturers. From the patients point of view, they will be affected because the introduction of lower-cost copies means that the new generics may not have the same effects ...
The following solution discusses with stakeholders in will be affected by legislation to regulate biotech medicines.